Pharmaceuticals
China drug developer Sumgen raises $32m
Addor Capital has led a RMB220 million ($32 million) Series B funding round for Hangzhou-based drug developer Sumgen Biotech.
Panacea leads $40m Series C for China's XWPharma
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Chinese mouse-based drug testing specialist raises $143m
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.
Long Hill invests $30m in Chinese O2O pharmacy player
Chinese digital healthcare platform inCarey has raised $30 million in an extended tranche of Series B funding from Long Hill Capital.
GL Ventures leads $58m Series B in China’s GemPharmatech
GemPharmatech, a Chinese company that provides genetically-modified mice for use in drug tests, has raised RMB400 million ($58.6 million) Series B led by GL Ventures, the VC arm of Hillhouse Capital.
DCP invests $283m in Chinese diabetes treatment player
DCP Capital Partners has acquired a 9% stake in Tonghua Dongbao Pharmaceutical, a Chinese pharmaceutical company specializing in diabetes treatment, for RMB1.94 billion ($283.7 million).
China healthcare big data player LinkDoc raises $102m
LinkDoc Technology, a Chinese healthcare big data company, has raised RMB700 million ($102 million) in an extended Series D round from CICC Capital, Youshan Capital, and iFOF, a fund-of-funds launched by CBC Capital and the Tianjin government.
Korean AI drug developer secures $14m Series B
Oncocross, a South Korean drug developer that uses artificial intelligence (AI) to identify new applications for treatments already in clinical trials, has raised KRW16.5 billion ($14 million) in Series B funding led by Smilegate Investment and GNTech...
China biotech player InxMed raises $19m
Ennovation Ventures, a Chinese life sciences and healthcare-focused investor, and China Growth Capital have led a RMB130 million ($19 million) round for local biotech developer InxMed.
Hillhouse leads $418m investment in China's I-Mab
I-Mab Biopharma, a private equity-backed Chinese drug developer that listed in the US as recently as January, has raised $418 million through a private placement.
Chinese drug developer Adlai Nortye raises $100m Series C
Adlai Nortye, a Chinese biopharma player specializing in cancer treatments, has raised nearly $100 million in Series C round led by Hong Kong-listed contrast research organisation (CRO) Tigermed and Shanghai-based Yingke PE.
Carlyle invests $260m in China's Salubris Pharmaceutical
The Carlyle Group has paid about $260 million for a 5% stake in Shenzhen-listed Salubris Pharmaceutical.
Creador invests $34m in India's Shriji Polymers
Creador has invested INR2.5 billion ($34 million) in Shriji Polymers India, a manufacturer of plastic pharmaceuticals packaging, taking a significant minority stake and providing an exit for Tata Capital.
RA Capital leads round for China's Connect Biopharma
Connect Biopharma, a drug developer based in China and the US, has raised $115 million in Series C funding led by RA Capital Management.
Blackstone agrees $2.3b carve-out from Japan's Takeda
Japan’s Takeda Pharmaceutical has agreed to sell a portfolio of over-the-counter (OTC) medicines and health products to The Blackstone Group for JPY242 billion ($2.3 billion).
China drug developer Dizal raises $100m
Chinese drug developer Dizal Pharmaceuticals has raised a $100 million round led by Lilly Asia Ventures, with participation from Sequoia Capital, Trinity Innovation Fund, and Wuxi NewForce Fund.
India pharma: The pills are popping
India’s pharmaceuticals industry is thriving on the macro ills of the day. Private equity is well placed to benefit, but the opportunity set is no secret
Hillhouse invests $830m in China’s JD Health
Hillhouse Capital has agreed to invest $830 million in JD Health, the healthcare unit of Chinese e-commerce giant JD.com, which will remain the majority shareholder.
Yunfeng backs take-private of China-US biotech player
Yunfeng Capital, a private equity firm co-founded by Jack Ma, is backing the privatization of Cellular Biomedicine, a US and China-based biotech developer.
Chinese CRO player Yaoyanshe raises $86m
Yaoyanshe, a Chinese contract research organization (CRO) for novel drugs, has raised RMB600 million ($86 million) across two rounds in the past eight months.
Huagai leads $43m round for China antibiotics developer
China-focused private equity firm Huagai Capital has a led a RMB300 million ($43 million) Series D round for antibiotics developer MicuRX Pharmaceuticals.
China's Sherpa closes debut US dollar fund at $200m
Sherpa Healthcare Partners, founded by former healthcare heads at Legend Capital, has closed its first US dollar fund at $200 million.
Legend leads $20m Series B for China's Exegenesis Bio
Chinese gene therapy specialist Exegenesis Bio has received $20 million in Series B funding led by Legend Capital. It will be used to support clinical development of the company’s drug portfolio.
Deal focus: Haihe's biotech out-licensing ambition
Warburg Pincus picked Haihe Pharmaceutical as its first bet on innovative drug development in China, having been convinced by the company's mature portfolio and international expansion plans